N/A N=28 Reducing Adenoviral Patient Infected Days
Conjunctivitis · Adenoviral Conjunctivitis
Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Topical Interferon Gamma-1b for Central Serous Chorioretinopathy
Retinal Disease · Macular Disease
Primary: Total Number of Severe Ocular Adverse Events Related to the Investigational Product — 0 Adverse Events
Phase 2 N=129 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46
Phase 2 N=11 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
Age-Related Macular Degeneration
Primary: Rate of Change in Area of Geographic Atrophy (GA) in the Study Eye at 24 Months as Compared to Baseline — 0.102 MPS DA/month
Phase 4 N=26 Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers
Glaucoma · Sedation
Primary: Change in Intraocular Pressure During Nitrous Oxide Sedation — 1.05 mmHg (difference in IOP) — p=>0.05
N/A N=76 Study of Brain, Reward, and Kids' Eating
Obesity, Childhood · Eating Behavior
Primary: Child Body Mass Index — 17.83; 18.78 kg/m-squred
Phase 2 N=56 Ranibizumab and Bevacizumab for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…
N/A N=56 Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye
Dry Eye Syndrome · Tear Film Insufficiency
Primary: Change From Baseline (V2) in Frequency and Severity of Dry Eye Symptoms (SANDE) Questionnaire Scores at Day 28±4 (End of Treatment) — -11.9; -16.6; -25.0; -26.5 mm
N/A N=20 Probing the Role of Feature Dimension Maps in Visual Cognition: Impact of Salience Level (Eye-tracking Follow-up Study)
Basic Science: Visual Attention in Healthy Participants · Attention
Primary: Gaze Position - Probability of Fixation at Salient Position — .209; .191; .207 Probability
N/A N=50 A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Medication Adherence · Glaucoma
Primary: Compliance Percentage — 73.9; 94.6; 93.99 percentage of days dose monitor recorded
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
Early Phase 1 N=8 Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
AMD
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
Phase 2 N=5 CNTF Implants for CNGB3 Achromatopsia
Eye Disease · Achromatopsia
Primary: Number of Adverse Events at Six Months Post-Implantation — 10 Adverse Events
Phase 2 N=6 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Phase 2 N=5 Sirolimus Injections for Autoimmune Scleritis
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…